Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Infections 2Urinary Tract Infections 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Biphenotypic, Acute 1Leukemia 1Glioblastoma 1Dendritic Cell Sarcoma, Interdigitating 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 29fludarabine phosphate 19Filgrastim 18Whole-Body Irradiation 15Mycophenolic Acid 15Methotrexate 15Peripheral Blood Stem Cell Transplantation 14Cytarabine 14Cyclosporine 13Busulfan 12Methylprednisolone 10Thiotepa 9Antilymphocyte Serum 9Tacrolimus 8Granulocyte Colony-Stimulating Factor 8Clofarabine 8Vincristine 7Radiotherapy 7Melphalan 7Cord Blood Stem Cell Transplantation 7fludarabine 6Leucovorin 6Dexamethasone 6merphos 5Mercaptopurine 5Etoposide 5Daunorubicin 5Cladribine 5Therapeutics 4Prednisone 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Biphenotypic, Acute × Trimethoprim, Sulfamethoxazole Drug Combination × Clear all
NCT00061945 2022-05-03

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
302 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡